O2-05-05: Results of the first-in-man study with the active Aβ Immunotherapy CAD106 in Alzheimer patients

  • Winblad B
  • Minthon L
  • Floesser A
  • et al.
N/ACitations
Citations of this article
20Readers
Mendeley users who have this article in their library.

Abstract

Background: CAD106 is an immunotherapeutic vaccine comprising the A61-6 peptide coupled to the Q6 virus-like particle. In animals, CAD106 induced A6-antibody titers without activating A6-reactive T-cells. Admin-istration of CAD106 to APP transgenic mice showed a reduction of amyloid accumulation in the brain. Methods: Safety, toler ability and immunogenic-ity of CAD106 was assessed in a first-in-man study CCAD106A2101, a 52-week, two-center, randomized, double-blind, placebo-controlled, parallel group study in patients with mild to moderate AD in Sweden. Patients were administered 50ug CAD106/placebo at weeks 0/6/18 in Cohort I, and 150ug CAD106/placebo at weeks 0/2/6 in Cohort II. Results: 58 Cau-casians (30m, 28f) with MMSE 16-26 were randomized in two semi-over-lapping cohorts. Results of Cohort I were presented previously. The mean age was 69.3 and 68 years in Cohort I and II, respectively. One Cohort II patient discontinued the study due to withdrawal of consent at week 26. No cases of meningoencephalitis were detected clinically, and no relevant con-cerns were raised by the repeated CSF and MRI assessments. Adverse events were predominantly mild. Between the cohorts, an increase in injection-related reactions was observed in patients receiving CAD106, with the most common reaction being injection-site erythema (CAD106 Cohort I: 4%; vs CAD106 Cohort II: 64%). Serious adverse events were reported in Cohort I for 4/24 (17%) patients on CAD106 and 1/7 (14%) on placebo, and in Cohort II for 4/22 (18%) patients on CAD106 and none on placebo. All SAEs were considered unrelated to the study medication by the inves-tigator and the DSMB. CAD106 induced a measur able specific antibody re sponse against A6 in 16/24 Cohort I patients and in 18/22 Cohort II patients. Peak mean Aβ IgG antibody titers were observed at week 8 in both cohorts with a 2-fold increase observed in Cohort II. Exploratory outcome measures (clinical, CSF and MRI) did not differ significantly in either treatment group or cohort. Conclusions: Overall, the results of this study support further development of CAD106. In the two ongoing studies in Europe and the US, further data on safety, toler ability and immunogenic-ity of CAD106 150 ug administered at 0/6/12 or 0/2/6 weeks are being gathered.

Cite

CITATION STYLE

APA

Winblad, B. G., Minthon, L., Floesser, A., Imbert, G., Dumortier, T., He, Y., … Andreasen, N. (2009). O2-05-05: Results of the first-in-man study with the active Aβ Immunotherapy CAD106 in Alzheimer patients. Alzheimer’s & Dementia, 5(4S_Part_4), P113–P114. https://doi.org/10.1016/j.jalz.2009.05.356

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free